This Phase 1, open label, randomized clinical trial will enroll 40 generally healthy, postmenopausal women aged 40-65 years old. Women will be randomized to one of two oral doses of MF101 for 4 weeks. Participants will be recruited at 3 clinical sites in the United States.

MF101 is an oral, non-hormonal, botanical agent being investigated for the treatment of menopausal hot flashes.

Inclusion Criteria (partial list):

• Postmenopausal women aged 40-65 years.
• Provide informed consent.
• Currently receive medical care from a health care provider. Other inclusions apply.

Exclusion Criteria (partial list):

• History of malignancy other than non-melanoma skin cancer or cervical cancer that was diagnosed and fully treated less than 5 years before screening.
• Unexplained uterine bleeding within 6 months prior to Screening.
• History of deep vein thrombosis or pulmonary embolism.
• Active liver disease or a history of impaired.
• Active gallbladder disease. Other exclusions apply.